Alfred Merriweather has been appointed chief financial officer of Adamas Pharmaceuticals.
“I am excited to join the Adamas team as the company transforms itself into a full commercial organization,” Merriweather said. “I have been impressed with Adamas’ proven discovery platform. I look forward to contributing my skills and experience to Adamas and its mission to improve the quality of life for patients with chronic neurologic conditions.”
Merriweather will lead Adamas’ accounting, finance, human resources, investor relations, SEC reporting and treasury functions.
Merriweather has more than two decades of experience serving in executive leadership and senior financial positions for many companies including Celera Corp., Laserscope, Monogram Biosciences, Raindance Technologies, and Verinata Health.
Merriweather is succeeding William Dawson in the role of CFO.
“I am sincerely grateful to Bill Dawson for his tremendous contribution to Adamas as CFO over the last three years, during which time he built a strong and capable finance and accounting organization as well as directly participated in raising over $170 million in capital to fund the company’s growth,” Adamas Chairman and CEO Gregory Went said. “I congratulate him on his retirement. Also, at this important time of transition for the company from a development organization to a full commercial entity, I am delighted to welcome Alf Merriweather to Adamas with his extensive commercial and financial experience.”